SynBioBeta Speaker

Viola Folli

D-Tails

Co-Founder & CSO

Viola Folli, PhD, is a physicist and Chief Scientific Officer at D-Tails Research, where she leads the development of next-generation biosensors and synthetic olfaction systems for non-invasive cancer diagnostics. She coordinates ULYSSES, a Horizon Europe Pathfinder Open project bringing together leading European universities and cancer centers to develop GPCR-based yeast biosensors capable of detecting cancer-associated volatile compounds in urine.Her research sits at the intersection of synthetic biology, receptor engineering, microfluidics, and AI-driven signal analysis. With a background in nonlinear optics and neurobiology, she previously developed an integrated C. elegans platform combining calcium imaging, behavioral mapping, and controlled sensory stimulation to study olfactory circuits.Viola is the inventor of multiple patents in cancer biosensing and lab-on-chip systems and the author of numerous peer-reviewed publications. Her work focuses on building biological sensing platforms that enable scalable, non-invasive early cancer detection.

Sessions Featuring

Viola

This Year

Femtech

•

12:45 PM

-

1:30 PM

Human Health

Early Detection. Precision Intervention. Real-World Deployment.

From circulating tumor DNA to AI-enabled diagnostics, liquid biopsies are collapsing the distance between biology and clinical action. This chamber convenes the scientists and clinicians leading that collapse — researchers who are not theorizing about the future of oncology, but building it: earlier signals, sharper targeting, smarter monitoring, and interventions that meet patients where the disease actually lives.

Featuring

Laura Glickman

Adjuvia

Co-Founder & CEO

Elizabeth Swenson

Teal Health

Medical Director

Viola Folli

D-Tails

Co-Founder & CSO

Andrea Stephany Diaz

OncoSwab

CEO & Founder

Zara Butte

Human Longevity

Physician

Femtech

•

12:45 PM

-

1:30 PM

Human Health

Early Detection. Precision Intervention. Real-World Deployment.

From circulating tumor DNA to AI-enabled diagnostics, liquid biopsies are collapsing the distance between biology and clinical action. This chamber convenes the scientists and clinicians leading that collapse — researchers who are not theorizing about the future of oncology, but building it: earlier signals, sharper targeting, smarter monitoring, and interventions that meet patients where the disease actually lives.

Featuring

Laura Glickman

Adjuvia

Co-Founder & CEO

Elizabeth Swenson

Teal Health

Medical Director

Viola Folli

D-Tails

Co-Founder & CSO

Andrea Stephany Diaz

OncoSwab

CEO & Founder

Zara Butte

Human Longevity

Physician

Previous Speakers Include